Golden State Wealth Management’s Aligos Therapeutics ALGS Stock Holding History

Golden State Wealth Management’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.4K	Hold	2,674	–	–	﹤0.01%	1004
2026 Q1	$19.9K	Hold	2,674	–	–	﹤0.01%	915
2025 Q4	$24.9K	Hold	2,674	–	–	﹤0.01%	875
2025 Q3	$26.2K	Hold	2,674	–	–	﹤0.01%	848
2025 Q2	$19.3K	Hold	2,674	–	–	﹤0.01%	895
2025 Q1	$22.1K	Hold	2,674	–	–	﹤0.01%	779
2024 Q4	$107K	Buy	+2,674	New	+$51.7K	0.02%	417
2022 Q1	$36K	Buy	674 +80	+13%	+$6.41K	0.01%	305
2021 Q4	$176K	Hold	594	–	–	0.03%	356
2021 Q3	$230K	Hold	594	–	–	0.05%	268
2021 Q2	$303K	Hold	594	–	–	0.07%	225
2021 Q1	$337K	Hold	594	–	–	0.11%	133
2020 Q4	$411K	Buy	+594	New	+$289K	0.12%	145

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Golden State Wealth Management's ALGS Position: Q2 2026 in Review

Golden State Wealth Management held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 2,674 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Golden State Wealth Management first reported a position in ALGS in Q4 2020 and has held it in 13 quarters since. The position peaked at $411K in Q4 2020. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Golden State Wealth Management held 2,674 shares of Aligos Therapeutics worth $15.4K as of Q2 2026.
Golden State Wealth Management left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1004 holding.
Golden State Wealth Management first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 13 quarters since.
Golden State Wealth Management's Aligos Therapeutics position peaked at $411K in Q4 2020.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.